Results of Phase 1a/1b Study of AbbVie's Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell L
Go back to Results of Phase 1a/1b Study of AbbVie's Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell L| AbbVie (NYSE: ABBV) | Delayed: 257.93 -4.97 (1.89%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $262.90 | 52 Week High | $68.12 | |||
| Open | $260.81 | 52 Week Low | $50.71 | |||
| Day High | $262.50 | P/E | 55.95 | |||
| Day Low | $257.25 | EPS | $4.61 | |||
| Volume | 1,969,053 | |||||
